Pulsar Vascular Management Team
Timothy Mills, Chairman has over twenty-five years of experience in biomedical research, corporate management and venture investing, currently a Managing Director at Sanderling Ventures in San Mateo CA. Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific in 1997. From July 1994 to July 1997, he was a director for Prograft Medical, a Target affiliate that was acquired by W.L Gore & Associates. Prior to joining Target in 1994, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare, now Edwards Life Science. Dr. Mills' previous academic appointments included service as the Director of the Artificial Heart Program at the University of California, Irvine Medical Center and membership in the University of California, San Francisco Radiology Department. Dr. Mills received his Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco School of Medicine, his M.S. in Electrical Engineering & Computer Science from the University of California, Berkeley, and his B.S. in Electrical Engineering from the University of Colorado, Boulder.
Rob Abrams, CEO has over 27 years of experience in biomedical device product development, research, operational management, new business development and strategic investments. Prior to joining Sanderling, Rob served 12 years at Boston Scientific Corp. as Group Vice President of New Business Development for BSC’s Cardiovascular Group Divisions, which included Neurovascular, Cardiac Surgery, Neuromodulation, Electrophysiology, and Peripheral Interventional Divisions. During his tenor at BSC, Rob completed acquisition of Smart Therapeutics, Precision Vascular Systems, Inc., and Advanced Bionics Corp. He also led the corporate program to explore technology for acute ischemic stroke therapy, and transacted several investments in that realm. Rob had become a part of BSC via their acquisition of Target Therapeutics, where he was Director of New Business Development. Prior to joining Target, Rob was Director of Product Development for LocalMed, Inc., a start-up dedicated to devices for catheter-based local drug delivery.From 1988 through 1995, Rob served various roles at Guidant Corporation in their Cardiovascular Business. He served as Director of R&D for the intrapreneurial Guidant Division, Heart Rhythm Technologies. Earlier, at Guidant’s Advanced Cardiovascular Systems (ACS) Division, he contributed to the product development and launch of guidewires, balloon catheters and stent technologies for interventional cardiology. Overall, Rob has 65 patents in medical devices. Prior to ACS, Rob’s entry into medical technology began at Howmedica Orthopedics, where he contributed to new bone in-growth technologies for hip and knee replacement prosthetic devices. Rob received his Bachelor of Science in Biomedical Engineering and Materials Science Engineering from the University of Pennsylvania, graduating summa cum laude.
Chad Roue, Vice President, Research & Development brings over 20 years of extensive technical and management experience in the medical devices field. Prior to Pulsar Vascular, he worked for Scimed, Target Therapeutics, (both acquired by Boston Scientific), Aspire Medical, Appriva, and Avantis. Mr. Roue has over 40 patents issued and many pending related to cardiology, catheters, stents and therapeutic aneurysm therapies, along with multiple commercial product launches. Mr. Roue holds a bachelor of science degree in metallurgical engineering from the University of Minnesota.